Baxter International Inc.

NYSE:BAX

Medical - Instruments & Supplies

Healthcare
$26.16 -5.23%

-$1.07 today

Market cap
$13.53B
Beta
0.64
P/E (TTM)
-9.1
EPS (TTM)
-$2.13
Dividend yield
1.03%
52W Low $15.73High $31.76

Volume 4.01M

Average 7.62M

Returns on capital

Baxter International Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-15.6%

avg 9.2%

ROIC

-1.8%

avg 3.5%

ROA

-4.8%

avg 5.3%

Analysis

ROIC is currently the strongest return metric at -1.8% versus its period average of 3.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Andrew Hider

Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and DirectorUSD 3.49M49——

John Terence Rogers

Executive Vice President & Chief Financial OfficerUSD 2.21M570<0.01%

Cynthia Carlisle

Executive Vice President & Chief Human Resources OfficerUSD 1.99M5117.81K<0.01%

David S. Rosenbloom

Executive Vice President & General CounselUSD 1.18M66138.22K0.03%

Maria Soriano

Group President of Infusion Therapies & PlatformsUSD 1.1M———

Bernie Heine

Interim Chief Accounting Officer & Controller—40——

Charles Patel

Senior Vice President & Chief Information Officer—56——

James W. Borzi

Executive Vice President & Chief Supply Chain Officer—6371.95K0.01%

Piero Novello

Senior Vice President and President of International————

Scott Kaplan

Senior Vice President of Quality, Regulatory & Patient Safety————

Steven Wallace

President of Advanced Surgery & Commercial Excellence—46——

Anita A. Zielinski

Interim CFO, Senior VP, Chief Accounting Officer & Controller—5346.28K<0.01%

Stacey Eisen

SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation————

Kevin Moran

Vice President & Head of Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A+3.8%
+2.9% (3yr)10 analysts
Net IncomeN/AN/AN/A
N/A10 analysts
EBITN/AN/AN/A
N/A10 analysts

Analysis

Recent growth has been strongest in Revenue at +3.8% over three years. Forward estimates point to Revenue at +2.9% (3yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Baxter International Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about BAX's management, answered from reported figures.

Who manages BAX?

Baxter International Inc. (BAX) lists 14 active executives. The top listed executive is Andrew Hider, Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director.

Are BAX insiders buying or selling?

Recent insider activity shows net buying of $36.08M.